Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01808573
Title A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Puma Biotechnology, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Lapatinib

Capecitabine + Neratinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.